Home Incyte Announces Global License Agreement With Jiangsu Hengrui Medicine For SHR-1210, An Investigational Anti-PD-1 Monoclonal Antibody
 

Keywords :   


Incyte Announces Global License Agreement With Jiangsu Hengrui Medicine For SHR-1210, An Investigational Anti-PD-1 Monoclonal Antibody

2015-09-02 08:04:11| drugdiscoveryonline News Articles

Incyte Corporation recently announced a global license and collaboration agreement with Jiangsu Hengrui Medicine Co., Ltd. for the development and commercialization of SHR-1210, an investigational anti-PD-1 monoclonal antibody

Tags: global agreement license medicine

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
28.09Tropical Storm Joyce Public Advisory Number 5
28.09Summary for Tropical Storm Joyce (AT1/AL112024)
28.09Post-Tropical Cyclone Helene Public Advisory Number 21
28.09Tropical Storm Joyce Forecast Discussion Number 5
28.09Tropical Storm Joyce Wind Speed Probabilities Number 5
28.09Tropical Storm Joyce Forecast Advisory Number 5
28.09Hurricane Isaac Graphics
28.09Hurricane Isaac Forecast Discussion Number 11
More »